Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

CJC-1295 (no DAC) + Ipamorelin Blend cycle length: what human studies ran

Not approved — research use only
Short answer: there is no established CJC-1295 (no DAC) + Ipamorelin Blend cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • CJC-1295 (no DAC) + Ipamorelin Blend combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established CJC-1295 (no DAC) + Ipamorelin Blend cycle length?
No. We found no human studies that report a treatment duration for CJC-1295 (no DAC) + Ipamorelin Blend.
What is the longest human study of CJC-1295 (no DAC) + Ipamorelin Blend?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
CJC-1295 (no DAC) + Ipamorelin Blend dosing reference Full research page

References

  1. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology. 2005
  2. Ipamorelin, the first selective growth hormone secretagogue Eur J Endocrinol. 1998
  3. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus J Pharmacol Exp Ther. 2009
  4. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians Am J Sports Med. 2026
  5. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats Growth Horm IGF Res. 2001
  6. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats Growth Horm IGF Res. 2009
  7. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Front Endocrinol (Lausanne). 2026
  8. Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Int J Pharm Compd. 2026
  9. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  10. PubMed search: "CJC-1295" AND ipamorelin (11 records, none an experiment on the combination; searched 22 October 2026) PubMed. 2026
  11. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
  12. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications JBJS Rev. 2026
  13. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs Mo Med. 2026
  14. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry Anal Bioanal Chem. 2013